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Francisella tularensis is the etiological agent of tularaemia and a CDC class A biological
threat agent. Few antibiotic classes are currently useful in treating tularaemia, including
the aminoglycosides gentamicin and streptomycin, fluoroquinolones, and tetracyclines.
However, treatment failures and relapses remain frequent and F. tularensis strains
resistant to antibiotics have been easily selected in vitro. In this study, we evaluated the
activity of new synthetic bis-indole derivatives against this pathogen. Minimum inhibitory
concentrations (MICs) of four compounds (dcm01 to dcm04) were determined for the
reference strains F. tularensis subsp. holarctica LVS NCTC10857, F. tularensis subsp.
novicida CIP56.12 and F. philomiragia ATCC25015, and for 41 clinical strains of F. tularensis
subsp. holarctica isolated in France. Minimal bactericidal concentrations (MBCs) were
determined for the dcm02 and dcm04 compounds for the LVS and two clinical strains.
Killing curves were also determined for the same three strains exposed to dcm04. All
tested bis-indole compounds were bacteriostatic against F. tularensis subsp. holarctica
strains, with a MIC90 of 8μg/mL for dcm01, dcm02, and dcm03, and 2μg/mL for dcm04.
Only one strain was resistant to both dcm01 and dcm03, with MICs > 32μg/mL. In
contrast, F. tularensis subsp. novicida was resistant to all derivatives and F. philomiragia
was only susceptible to dcm02 and dcm04, with MICs of 16 and 4μg/mL, respectively.
MBC and killing curve experiments revealed significant bactericidal activity (i.e., 3-log
reduction of the bacterial inoculum) of the dcm02 and dcm04 compounds only for
the LVS strain. In conclusion, we have identified novel synthetic bis-indole compounds
that are active against F. tularensis subsp. holarctica. They may be drug candidates for
the development of new therapeutic alternatives for tularaemia treatment. Their further
characterization is needed, especially identification of their bacterial targets.
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INTRODUCTION
Francisella tularensis, the agent of the zoonosis tularaemia, may
cause severe to fatal human infections. This intracellular, Gram-
negative bacterium is highly infectious for humans and many
animal species. No human-to-human transmission has been
described so far and human infection may occur through direct
contact with infected animals, ingestion of contaminated meat
or water, arthropod bites, contact with contaminated environ-
ments and laboratory exposure to F. tularensis cultures (Dennis
et al., 2001; Maurin et al., 2011). F. tularensis is a class A biological
threat agent according to the CDC (Centers for Diseases Control
and Prevention, Atlanta, Georgia, USA). The highly virulent F.
tularensis subsp. tularensis strains (Jellison type A) are located
in North America, whereas F. tularensis subsp. holarctica strains
(Jellison type B) are found throughout the northern hemisphere.
In Europe, tularaemia cases are often sporadic (Maurin et al.,
2011), but outbreaks have recently been reported in many coun-
tries, including in Spain, Norway and Sweden (Pérez-Castrillón
et al., 2001; Larssen et al., 2011; Rydén et al., 2012). The first-line
therapy of tularaemia is based on a reduced number of antibiotics,
including the aminoglycosides (gentamicin and streptomycin),
the tetracyclines (e.g., doxycycline), and the fluoroquinolones
(e.g., ciprofloxacin) (Johansson et al., 2002). Treatment duration
is usually 7–10 days for gentamicin and ciprofloxacin, and 2–3
weeks for doxycycline. However, high rates of failure and relapse
are observed in tularaemia patients, especially when treatment
is delayed and/or lymph node suppuration occurs (Rotem et al.,
2012).
The aminoglycosides such as gentamicin and streptomycin
have a bactericidal activity against F. tularensis in vitro, and their
use in tularaemia patients is associated with almost 100% cure
rates (Kaya et al., 2011; Rotem et al., 2012). However, they are
nephro- and ototoxic and can only be administrated parenterally
(Tärnvik and Chu, 2007). Gentamicin is currently used in many
countries where streptomycin is no longer available. However,
treatment failures with this antibiotic have recently been reported
in 11 paediatric patients with oropharyngeal tularaemia in
Turkey, with successful recovery after switching to streptomycin
(Kaya et al., 2011). Doxycycline can be administrated orally, with
few side effects. However, the tetracyclines are contraindicated in
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children under 8 years of age and in pregnant women because
of the risk of permanent staining of the dental enamel and bone
toxicity in the foetus (Tärnvik and Chu, 2007; Kaya et al., 2011).
Treatment with this bacteriostatic antibiotic is associated with
higher relapse rates as compared to aminoglycosides and flu-
oroquinolones, especially when treatment is delayed and/or of
short duration (Dennis et al., 2001; Tärnvik and Chu, 2007).
Doxycycline is administered for a minimum of 14 days (Dennis
et al., 2001; Tärnvik and Chu, 2007). The fluoroquinolones (espe-
cially ciprofloxacin and levofloxacin) are preferred as first-line
drugs for treatment of tularaemia cases of mild to moderate
severity (Johansson et al., 2002). They are bactericidal against F.
tularensis in vitro, orally administrable, and have few side effects.
They can be administrated to young children but not to pregnant
women (Johansson et al., 2000; Dennis et al., 2001; Tärnvik and
Chu, 2007; Kaya et al., 2011). Ciprofloxacin is recommended as
first-line drug in case F. tularensis is used as a biological weapon
(Dennis et al., 2001; Rotem et al., 2012).
Other antibiotics such as the beta-lactams, the macrolides,
cotrimoxazole, chloramphenicol, and rifampicin are not rec-
ommended for treatment of tularaemia. Beta-lactams are not
effective both because they are inactivated by the class A beta-
lactamase produced by F. tularensis (Antunes et al., 2012) and
they are poorly effective against the intracellular form of this
pathogen (Maurin et al., 2000). The macrolides are considered
unreliable for treatment of tularaemia because most F. tularen-
sis strains have natural high-level resistance to these antibiotics.
Only azithromycin may be a possible alternative in pregnant
women infected with type B biovar I strains (Dentan et al., 2013).
Chloramphenicol and cotrimoxazole are poorly effective in vitro
and potentially associated with severe side effects (Tärnvik and
Chu, 2007). Rifampicin is active against F. tularensis in vitro, but
its use as a monotherapy is usually associated with rapid selection
of resistant mutants.
No natural strains of F. tularensis with acquired resistance
to gentamicin, fluoroquinolones or doxycycline have been iso-
lated so far. However, in vitro experiments have shown that
mutants resistant to fluoroquinolones, rifampicin or macrolides
can be selected easily (Tärnvik and Chu, 2007; Gestin et al., 2010;
Sutera et al., 2014). At present, treatment failures and relapses
are considered to be primarily related to delayed administration
of appropriate antibiotic therapy rather than in vivo selection
of antibiotic-resistant mutants (Dennis et al., 2001; Johansson
et al., 2002; Kaya et al., 2011; Rotem et al., 2012). However,
the bioengineering of genetically modified strains of F. tularensis
resistant to first-line drugs for use as a biological warfare agent
is a major concern. Thus, innovative antibiotics with original
structures and bacterial targets, active against this highly virulent
pathogen, would be beneficial not only to improve treatment effi-
cacy in tularaemia patients, but also to reinforce our preparedness
against the misuse of antibiotic-resistant F. tularensis strains.
We recently identified synthetic bis-indole derivatives as new
antistaphylococcal compounds with preserved activity against
multi-drug resistant strains of Staphylococcus aureus, including
MRSA strains (Denis et al., 2013a,b). In this study, we evalu-
ated the activity of four of the leading compounds against clinical
isolates of F. tularensis subsp. holarctica.
MATERIALS AND METHODS
BIS-INDOLIC COMPOUNDS AND ANTIBIOTICS
The four bis-indolic compounds evaluated in this study (dcm01,
dcm02, dcm03, and dcm04) were synthesized by the DCM
(Département de Chimie Moléculaire, Université Joseph Fourier
Grenoble-1, Grenoble, France) according to previously pub-
lished protocols (Denis et al., 2013a,b). The structures of the
tested bis-indole compounds are presented on Figure 1. We also
used gentamicin (Panpharma, Fougères, France) and doxycycline
(Sigma-Aldrich, Lyon, France) as controls. Stock solutions of the
bis-indolic compounds were prepared at 12.8 g/L in 100%DMSO
(Sigma-Aldrich, Lyon, France) and stock solutions of gentamicin
and doxycycline were prepared in sterile distilled water. All were
kept frozen at −80◦C until used.
BACTERIAL STRAINS
All experiments were conducted in a biosafety level 3 labora-
tory. The use of F. tularensis strains was carried out under the
approval of ANSM (Agence nationale de sécurité du médica-
ment et des produits de santé). We tested 41 isolates (Ft1–Ft41)
of F. tularensis subsp. holarctica identified to the subspecies level
in our laboratory (French reference center for Francisella) by
amplification and sequencing of the intergenic 16S-23S rRNA
region (Maurin et al., 2011). Four isolates were obtained from
dead hares and the 37 others from human samples (Table 1).
The clinical strains corresponded to independent and sporadic
tularaemia cases occurring throughout France between 2004 and
2013 (Maurin et al., 2011).We also tested reference strains includ-
ing F. tularensis subsp. holarctica LVS NCTC10857, F. tularensis
subsp. novicida CIP56.12 and F. philomiragia ATCC25015. S.
aureus ATCC29213 was tested as a control strain susceptible to
the tested bis-indole compounds (Denis et al., 2013a,b). The
reference bacterial strains were purchased from the American
Type Culture Collection (ATCC, Mannasas, VA, USA) or the
Collection of the Pasteur Institute (CIP, Centre de Ressource
Biologique de l’Institut Pasteur, Paris, France). All strains are kept
frozen in cryotubes (MastDiagnostic, Amiens, France) at −80◦C.
When needed, they are grown on chocolate agar supplemented
FIGURE 1 | Structures of the four bis-indole compounds.
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Table 1 | Sources of the 41 isolates of F. tularensis subsp. holarctica
(Ft1 to Ft41) used in this study.
Strain Host Year of isolation Clinical sample
Ft1 Animal UNK Hare tissue
Ft2 Animal UNK Hare tissue
Ft3 Animal UNK Hare tissue
Ft4 Animal UNK Hare tissue
Ft5 Human 2004 Blood culture
Ft6 Human 2007 Blood culture
Ft7 Human 2006 Conjunctivitis
Ft8 Human 2007 Cutaneous ulcer
Ft9 Human 2007 Blood culture
Ft10 Human 2008 Mediastinal lymph node
Ft11 Human 2008 Pharynx
Ft12 Human 2008 Pharynx
Ft13 Human 2008 Pharynx
Ft14 Human 2008 Blood culture
Ft15 Human 2008 Cerebrospinal fluid
Ft16 Human 2008 UNK
Ft17 Human 2008 UNK
Ft18 Human 2008 Blood culture
Ft19 Human 2008 Blood culture
Ft20 Human 2008 Skin ulcer
Ft21 Human 2008 Conjunctivitis
Ft22 Human 2009 Whitlow
Ft23 Human 2009 Middle ear
Ft24 Human 2009 Lymph node
Ft25 Human 2010 Blood culture
Ft26 Human 2010 Blood culture
Ft27 Human 2010 Blood culture
Ft28 Human 2010 Lymph node
Ft29 Human 2010 Blood culture
Ft30 Human 2011 Lymph node
Ft31 Human 2011 UNK
Ft32 Human 2012 UNK
Ft33 Human 2011 Blood culture
Ft34 Human 2012 Blood culture
Ft35 Human 2012 Finger abscess
Ft36 Human 2012 UNK
Ft37 Human 2010 Blood culture
Ft38 Human 2012 Blood culture
Ft39 Human 2012 Whitlow
Ft40 Human 2012 Pleural fluid
Ft41 Human 2013 Pleural fluid
UNK, unknown.
with Polyvitex® (CHA-PVXmedium, bioMérieux, Marcy l’Etoile,
France) at 37◦C in a 5% CO2-enriched atmosphere.
DETERMINATION OF THE MINIMUM INHIBITORY CONCENTRATIONS
Minimum inhibitory concentrations (MICs) of the four
bis-indolic compounds were determined against S. aureus
ATCC29213, F. philomiragia ATCC25015 and all F. tularensis
strains, using a broth microdilution method recommended
by the Clinical and Laboratory Standards Institute (CLSI;
M07-A8Vol. 29, No. 2). Mueller-Hinton 2 broth supplemented
with 2% PolyViteX® (MH2-PVX, bioMérieux, Marcy L’Etoile,
France) was used as the antibiotic susceptibility testing medium
for F. tularensis strains because of their fastidious nature. MH2
alone was used for other species. One row of a 96-well microtiter
plate was filled with 75μL of twofold serial dilutions of the
tested bis-indolic compound in MH2-PVX medium, so as to
obtain final bis-indolic concentrations ranging from 0.06 to
32μg/mL in 0.5% DMSO. A bacterial inoculum (75μL per well,
5 × 105 CFU/mL of final inoculum) was then added to each well.
Antibiotic free cultures containing 0.5% DMSO were used as
DMSO toxicity controls. MH2-PVX medium with 0.5% DMSO
served as a negative control. Microplates were incubated at 37◦C
in a 5% CO2 atmosphere. The MICs were read after 18 h culture
incubation for S. aureus ATCC29213 and 48 h for F. tularen-
sis strains. MICs corresponded to the minimum bis-indolic
compound concentration that allowed complete inhibition of
visual growth of bacteria. Experiments were conducted at least
twice to confirm results. Following the same procedure but
without DMSO, the MICs of gentamicin and doxycycline were
determined against F. tularensis subsp. holarctica Ft6 and Ft24
strains and the control strain S. aureus ATCC29213.
DETERMINATION OF THE MINIMUM BACTERICIDAL
CONCENTRATIONS
Minimum bactericidal concentrations (MBCs) were determined
in triplicate experiments following CLSI recommendations
(CLSI, M26-A, Vol. 19, No. 18), for the two most active com-
pounds (dcm02 and dcm04) against three F. tularensis subsp.
holarctica strains: the LVS strain and the two clinical strains
Ft6 and Ft24. We used the same microdilution broth method
described for MIC determination, but the primary bacterial
inoculumwas 106 CFU/mL.MBCs of gentamicin and doxycycline
were determined in parallel as a bactericidal and a bacterio-
static control, respectively. After 48 h incubation at 37◦C in a 5%
CO2atmosphere, MBCs were determined by plating 50μL of ten-
fold serial dilutions of the bacterial suspensions of wells with no
visible growth, and of the antibiotic-free control well, onto CHA-
PVXmedium. CFU counts were determined after 72 h incubation
of the plates at 37◦C, in a 5% CO2 atmosphere. The detection
limit was 20CFU/mL. The MBC corresponded to the minimal
antibiotic concentration which resulted in at least 99.9% reduc-
tion of the primary bacterial inoculum (i.e., 3 log10 reduction of
bacterial titers).
TIME-KILL CURVES
Time-kill curves were determined for the LVS, Ft6, and Ft24
strains and the leading dcm04 compound. The primary inoculum
calibrated at 106 CFU/mL was prepared in MH2-PVX medium
and split into five 5-mL aliquots: one drug-free control; three oth-
ers receiving 4, 8, and 16 times, respectively, the MIC of dcm04
for the tested strain, with 0.5% final concentration of DMSO in
all three aliquots; and the last one receiving eight times theMIC of
gentamicin for the tested strain, used as a positive control. Sterile
MH2-PVX medium with 0.5% DMSO served as a negative con-
trol. Cultures were incubated 48 h at 37◦C in 5% CO2. At 0, 6, 12,
24, 36, and 48 h of incubation, a 50-μL aliquot was taken from
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Table 2 | MICs (µg/mL) of Francisella strains for the four bis-indolic compounds: dcm01, dcm02, dcm03, and dcm04.
Bis-indole compound F. tularensis subsp. holarctica subsp. novicida F. philomiragia
FT1 to Ft41 LVS CIP 56.12 ATCC25015
MIC range MIC50 MIC90 MIC MIC MIC
dcm01 2–>32 4 8 2 >32 >32
dcm02 4– 8 4 8 2 32 16
dcm03 2–>32 4 8 2 >32 >32
dcm04 2– 4 2 2 1 >32 4
each culture after shaking. Then 50μL of ten-fold serial dilutions
of each aliquot was plated on CHA-PVX medium. CFU counts
were determined after 72 h incubation of the plates at 37◦C in
5% CO2. The detection limit was 20CFU/mL. A 3-log10 or more
reduction of the primary bacterial inoculum at any incubation
time was considered a significant bactericidal effect. Experiments
were conducted at least twice to confirm the results.
STATISTICAL ANALYSIS
A statistically significant decrease of viable bacterial counts in
MBC assays was evaluated by one-tailed Student t-test using
Statview® software. For each antibiotic concentration tested, we
compared the bacterial count obtained after 48 h of incubation of
cultures to the primary inoculum [i.e., log(N/N0)] and to a 3-log
reduction cutoff. Significance was defined as a p-value< 0.05.
RESULTS
ALL TESTED SYNTHETIC BIS-INDOLIC COMPOUNDS ARE ACTIVE
AGAINST F. TULARENSIS SUBSP. HOLARCTICA BUT NOT
F. TULARENSIS SUBSP. NOVICIDA
MICs are represented in Tables 2, 3. Almost all F. tularensis strains
tested were susceptible to the four bis-indole derivatives. In con-
trast, the Ft5 strain was susceptible to dcm02 and dcm04 (MIC =
8 and 2μg/mL, respectively), but resistant to dcm01 and dcm03
(MICs> 32μg/mL). Dcm04 was the most active bis-indole com-
pound with MICs ranging from 2 to 4μg/mL and a MIC90of
2μg/mL. The MIC90of the three other compounds was 8mg/L.
It should be noted that prolonged incubation of cultures only
increasedMICs by one dilution for some compounds. In compar-
ison, the MIC of gentamicin against the LVS, Ft6 and Ft24 strains
was 0.25μg/mL and the MIC of doxycycline was 0.125μg/mL
against LVS and 0.25μg/mL against the Ft6 and Ft24 strains. As
for control strains, the F. tularensis subsp. holartica LVS strain
was susceptible to the four bis-indole derivatives with a MIC of
1–2μg/mL. In contrast, the reference F. tularensis subsp. novi-
cida strain and the reference F. philomiragia strain were more
resistant to these compounds. MICs of all bis-indole derivatives
were ≥32μg/mL for F. tularensis subsp. novicida, whereas dcm02
and dcm04 displayed lower MICs (16 and 4μg/mL, respectively)
against F. philomiragia.
MBC DETERMINATION AND TIME-KILL STUDIES REVEALED A
BACTERICIDAL ACTIVITY AGAINST THE LVS STRAIN BUT ONLY
BACTERIOSTATIC ACTIVITY AGAINST THE Ft6 AND Ft24 STRAINS
The bactericidal activities of the bis-indole compounds, gentam-
icin and doxycycline, were determined for the LVS, Ft6, and Ft24
Table 3 | MICs (µg/mL) and MBCs (µg/mL) of the tree F. tularensis

















2 (4) 1 (4) 0.25 (2) 0.125
strains (Figures 2, 3). As expected, gentamicin displayed bacteri-
cidal activity against the three strains (> 3 log10 reduction of the
primary bacterial inoculum, p < 0.01), with MBCs of 1μg/mL
for the LVS strain and 2μg/mL for Ft6 and Ft24 strains. As
for doxycycline, a significant reduction of the primary bacterial
inoculum was observed (i.e., between 1 and 2 log10 at MIC × 64
for the LVS strain and MIC × 32 for the Ft6 and Ft24 strains;
p < 0.01) but the 3-log reduction cutoff was not reached.
MBCs of the dcm02 and dcm04 compounds (4μg/mL for both
compounds) were only two or four times their respective MICs
for the LVS strain (Table 3), respectively. In contrast, MBCs could
not be determined for the dcm02 and dcm04 compounds against
the Ft6 and Ft24 strains. Here again reduction of the primary
bacterial inoculum was significant (2-log reduction at concentra-
tions up to MIC × 8 for dcm02 and MIC × 16 for dcm04, p <
0.01) but did not reached the 3-log cutoff. Higher concentrations
of these compounds could not be tested because of their poor
solubility.
Time-kill studies revealed a 3-log10 reduction of the primary
inoculum of the LVS strain after 12 h incubation for gentamicin
(MIC × 8) and 24 h for dcm04 (MIC × 4). As for dcm04, the
same bactericidal kinetics were observed at 4, 8, and 16 times the
MIC of this compound for the LVS strain. As for the Ft6 and Ft24
strains, we observed a progressive decrease of the bacterial load
over the first 48 h of contact with dcm04 (Figure 3), but a 3-log10
reduction of the primary bacterial inoculum was never reached.
Thus, the dcm02 and dcm04 compounds were only bacteriostatic
against the clinical strains of F. tularensis subsp. holarctica.
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FIGURE 2 | MBC determination figures for dcm02, dcm04, gentamicin, and doxycycline against F. tularensis subsp. holarctica LVS, Ft6, and Ft24 strains,
performed in triplicate experiments. Bacterial survival was monitored by measuring CFU/mL after 48 h of incubation. Error bars represent standard deviation.
DISCUSSION
Among the currently developed therapeutic alternatives for
tularaemia, two promising original classes of compounds have
recently been identified. First, substituted diphenyl ethers have
demonstrated potent inhibition of ftuFabI Enoyl-acyl carrier pro-
tein reductase (England et al., 2009). This enzyme, absent in
human cells, plays a key role in the type II fatty acid biosynthe-
sis and has proved to be a useful target for growth inhibition of
various pathogens such as Mycobacterium tuberculosis, S. aureus
and Plasmodium falciparum (England et al., 2009; Lu et al.,
2009; Hevener et al., 2012; Mehboob et al., 2012; Kingry et al.,
2013). The leading compound SBPT04 has an MIC of 0.16 ±
0.06μg/mL against F. tularensis LVS and Schu4 strains and also
has a bactericidal activity with a MBC of 0.25μg/mL. In a murine
model of F. tularensis infection, this compound cleared bacte-
ria by day 4 of treatment, without any relapse the following 30
days post-treatment (England et al., 2009). Secondly, screening
of a library of more than 1000 2,5,6- and 2,5,7-trisubstituted
benzimidazoles identified 21 leading derivatives exhibiting MICs
between 0.35 and 48.6μg/mL against the F. tularensis LVS strain.
Their bacterial target remains uncharacterized, but these com-
pounds may block polymerization of FtsZ, which is a homolog
of tubulin/microtubule proteins found in eukaryotes, thus inter-
fering with cell division processes (Kumar et al., 2013).
Here, we report that bis-indole derivatives in which the
two indole groups are linked either with an amide (dcm01
and dcm02) or an α-keto-amide (dcm03 and dcm04) central
linker exhibit antimicrobial activity against F. tularensis subsp.
holarctica. These compounds were previously characterized as
anti-staphylococcal drugs active against methicillin-resistant,
vancomycin-intermediate, and fluoroquinolone-resistant S.
aureus strains (Denis et al., 2013a,b). In this study, the 24 bis-
indolic molecules evaluated were inactive against Gram-negative
bacteria, including enterobacterial species (Escherichia coli,
Klebsiella pneumoniae, Serratia marcescens, and Enterobacter
cloacae), Pseudomonas aeruginosa and Acinetobacter bau-
mannii. The MICs of two bis-indolic derivatives were lower
(16μg/mL) against Haemophilus influenzae. The cytotoxicity
of the four bis-indole compounds we tested against F. tularen-
sis strains was previously evaluated using three different cell
lines: KB (human mouth carcinoma), MCR5 (human lung
fibroblast) and HCT116 (human colon tumor) (Denis et al.,
2013a,b). The IC50 determined using the HCT116 cell line
were 1–5 times higher than the MICs found for F. tularensis
strains.
We found a significant bacteriostatic activity of these tested
bis-indole derivatives against 41 strains of F. tularensis subsp.
holarctica isolated in France. Dcm04 appeared to be the most
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FIGURE 3 | Time-kill kinetics of dcm04 at 4, 8, and 16 times the MIC against F. tularensis subsp. holarctica LVS, Ft6, and Ft24 strains. Gentamicin at
eight times the MIC was used as control of a bactericidal antibiotic. Two independent assays were performed but only one representative experiment is shown.
effective compound with a MIC90 of 2μg/mL. The MICs ranged
from 2 to 16μg/mL when considering all four bis-indole com-
pounds, except for a single strain that displayed higher MICs
for the dcm01 and dcm03 compounds. The variations in antibi-
otic activities between the four compounds (especially between
dcm01 and dcm03 vs. dcm02 and dcm04) may be related to dif-
ferences in chemical structure, especially the presence of a large
CH2NHBoc chemical group in dcm01 and dcm03, whereas it is
replaced by a methyl in dcm02 and dcm04. This large chemical
group may limit access of dcm01 and dcm03 to their bacterial
target or limit their penetration within bacteria. Surprisingly, the
dcm02 and dcm04 compounds displayed a bactericidal activity
against the virulence-attenuated LVS strain, but not the Ft6 and
Ft24 clinical strains of F. tularensis subsp. holarctica. This was
demonstrated both by MBC determinations and in killing curve
experiments. The bactericidal activity of dcm04 against the LVS
strain was not concentration-dependent but time-dependent.
Hopefully, further structural optimization of these bis-indolic
compounds and identification of their bacterial targets may
enable us to obtain the same bactericidal activity for clinical
strains of F. tularensis subsp. holarctica.
The activity of the bis-indole compounds also showed
Francisella species and subspecies specificity, since these com-
pounds were active against F. tularensis subsp. holarctica, only
partially active (dcm02 and dcm04) against F. philomiragia and
inactive against F. tularensis subsp. novicida. As a result, F. tularen-
sis subsp. novicida cannot be used as an experimental model to
identify the bacterial targets of these compounds, nor to eval-
uate the in vivo activity of the bis-indoles. Comparison of the
complete genomes of F. tularensis subsp. holarctica LVS, OSU18,
and FSC200, and that of F. tularensis subsp. tularensis Schu
S4, previously identified a relatively limited number of specific
genetic alterations (Petrosino et al., 2006; Rohmer et al., 2006)
in the attenuated LVS strain. This might help in further investi-
gations to search for an antibacterial target of these compounds
in F. tularensis, or at least to explain the differences observed in
susceptibility to the bis-indoles. Working hypotheses may include
an increased affinity of the bis-indoles for their bacterial target
in the LVS strain, a reduced penetration of the bis-indole in the
clinical strains as compared to the LVS strain, partial inactiva-
tion of the bis-indoles in the clinical strains but not in the LVS
strain, an escape pathway to the action of the bis-indoles in clin-
ical strains but not in the LVS strain, and a lower efflux of these
molecules in the LVS strain. Another hypothesis is that the bis-
indole compounds are more active against the LVS strain because
it belongs to the type B biovar II strains of F. tularensis, whereas
the 41 clinical strains belong to biovar I of this sub-species. Biovar
II strains naturally resistant to erythromycin are found in Central
and Eastern Europe, and Asia (Kudelina and Olsufiev, 1980),
whereas only the erythromycin-susceptible biovar I strains are
found in France. We did not evaluate the activity of the bis-
indoles against type A F. tularensis strains. Testing the activity of
these compounds against a larger panel of F. tularensis strains will
be needed to assess potential variability in susceptibility among
different sub-species and biovars.
In conclusion, we have identified novel synthetic bis-indole
compounds active against F. tularensis subsp. holarctica but
not the closely related bacteria F. tularensis subsp. novicida
and F. philomiragia. These compounds may be drug can-
didates for the development of new therapeutic alternatives
for tularaemia treatment. Their bacterial targets remain to be
characterized.
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